Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NDORMS research M Sanni Ali received a Young Investigator Award at this week’s National Osteoporosis Society Conference 2016, held in Birmingham.

Sanni presented work on a non-experimental study using SIDIAP, a real life database from Catalonia, North East Spain. The Prieto-Alhambra Group - Musculoskeletal Pharmaco- and Device epidemiology - at NDORMS evaluated the comparative risk of fragility fracture in type 2 diabetic patients using different anti-diabetic medications.

It is estimated that 415 million people between the ages of 20 and 70 worldwide have diabetes, with the condition expected to affect one person in 10 by 2040 - 642 million. In addition, it is estimated globally that 1 in 2 adults with Type 2 diabetes are undiagnosed.

Sanni said: "We found that the risk of fragility fracture is higher in insulin users compared to patients who are on metformin mono-therapy. This data is very useful to manage the condition in the broader context of a patient's life and hopefully can inform new therapeutic approaches for these patients."

Together with another abstract, Sanni's submitted work to the conference received the highest score from reviewers.

Speaking on the award, Sanni said: "This is a unique conference and I was honoured to meet the world's most influential scientists in the field of osteoporosis. Having my research recognised in such a setting was wonderful and I would like to thank the reviewers and my team for the opportunity."

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.